Philips takes POC testing to new heights with Magnotech solution
This article was originally published in Clinica
Executive Summary
Point-of-care testing in the healthcare setting is a potentially very lucrative sector, but the market has stalled somewhat of late. “POC has certainly not grown very fast recently,” according to Marcel van Kasteel, vice-president of Philips and CEO of Philips Handheld Immunoassays. “The current world market is valued at some $3-4bn,” he told Clinica, “but it has the potential to reach $15bn”. For that to happen, though, a structural change in the market will be needed, driven by the introduction of new technologies.